Vyome Holdings
CompanyUnited States
Vyome Holdings develops one asset, preclinical (VT-1908 in ocular inflammation). Mostly small molecule acting on inflammation, IMPDH1 and IMPDH2; based in the United States.
- 1
- Asset
- Furthest stage
- Preclinical
- 0
- Trials
- 0
- Signals
Pipeline
1Inosine monophosphate dehydrogenase inhibitor that suppresses de novo purine synthesis in lymphocytes
Preclinical, Small molecule, Inflammation, IMPDH1, ocular inflammation
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Similar companies6